Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy
Clinical trial NCT05662813 · UNKNOWN
Trial details
- NCT number
- NCT05662813
- Sponsor
- West China Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-09
- Primary completion
- 2023-12-30
- Enrollment
- 55
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.